Cardiac Neoplasia

Cardiac neoplasia refers to a diverse group of primary and metastatic tumors that arise within the heart, pericardium, or great vessels. These neoplasms can be benign or malignant, and their clinical significance is determined by their location, size, growth rate, and invasiveness. Primary cardiac tumors are rare in dogs and cats, with hemangiosarcoma being the most common in dogs, while lymphoma and chemodectoma are also reported. Metastatic cardiac tumors are more frequent than primary ones, often originating from splenic, hepatic, or pulmonary hemangiosarcomas, or from mammary gland carcinomas. The clinical presentation varies from asymptomatic incidental findings to acute cardiac tamponade, right-sided congestive heart failure, or arrhythmias. Surgical management is primarily indicated for pericardial effusion (via pericardectomy) or for resection of well-circumscribed masses, such as right atrial hemangiosarcoma or heart base tumors. The prognosis depends on tumor type, stage, and completeness of surgical excision.

The exact etiology of primary cardiac neoplasia remains largely unknown, but several factors have been implicated. Genetic predispositions are recognized in certain breeds, such as the Golden Retriever and German Shepherd for hemangiosarcoma, suggesting a heritable component. Environmental factors, including exposure to carcinogens like ionizing radiation or certain chemicals, may contribute to tumorigenesis. Chronic inflammation or viral infections have been hypothesized but not definitively proven. For metastatic cardiac tumors, the etiology is the dissemination of malignant cells from a primary site, often via hematogenous or lymphatic routes. The heart's high vascularity and the presence of endothelial cells make it a common site for metastasis. Specific molecular mechanisms involve dysregulation of angiogenesis, apoptosis, and cell cycle control, with mutations in tumor suppressor genes (e.g., p53) and oncogenes (e.g., KIT) being implicated in some tumor types.

Cardiac neoplasia is uncommon in small animal practice, with an estimated incidence of 0.1-0.5% in dogs and cats. Primary cardiac tumors account for approximately 0.1-0.2% of all canine tumors. Hemangiosarcoma is the most common primary cardiac tumor in dogs, representing about 70% of cases, and is predominantly seen in middle-aged to older dogs (8-12 years). Breeds at increased risk include Golden Retrievers, German Shepherds, Labrador Retrievers, and Boxers. Male dogs may be slightly overrepresented. Feline cardiac tumors are even rarer, with lymphoma being the most common, often associated with feline leukemia virus (FeLV) infection. Other primary tumors include chemodectoma (heart base tumor), which is more common in brachycephalic breeds like Boxers and Bulldogs, and mesothelioma, which can affect the pericardium. Metastatic cardiac tumors are more common than primary ones, with hemangiosarcoma, lymphoma, and mammary gland carcinoma being frequent sources. The overall prevalence of cardiac metastasis in dogs with malignant neoplasia is reported to be up to 25%.

The pathophysiology of cardiac neoplasia is multifaceted and depends on the tumor's location and growth pattern. Tumors can arise in the myocardium, endocardium, or pericardium. Right atrial hemangiosarcoma, the most common primary cardiac tumor, typically grows as a hemorrhagic, infiltrative mass that disrupts the atrial wall and often extends into the pericardial space. This leads to hemorrhage and subsequent pericardial effusion, which can rapidly progress to cardiac tamponade. Cardiac tamponade occurs when intrapericardial pressure exceeds intracardiac filling pressures, causing impaired diastolic filling of the right ventricle, reduced stroke volume, and decreased cardiac output. This results in clinical signs of right-sided heart failure, such as ascites, jugular venous distension, and weakness. Heart base tumors (chemodectomas) arise from chemoreceptor cells near the aortic body and can cause compression of the great vessels, leading to outflow obstruction or arrhythmias. Myocardial tumors, such as rhabdomyosarcoma or fibrosarcoma, can disrupt the conduction system, causing arrhythmias, or impair contractility, leading to congestive heart failure. Metastatic tumors often cause diffuse infiltration of the myocardium, resulting in arrhythmias and myocardial dysfunction. The systemic effects of cardiac neoplasia include paraneoplastic syndromes, such as cachexia, anemia, and hypercalcemia, which further compromise the patient's health.

Several factors predispose animals to cardiac neoplasia. Breed predisposition is significant, with Golden Retrievers and German Shepherds having a higher risk for hemangiosarcoma, likely due to genetic factors. Age is a risk factor, as most cardiac tumors occur in older animals. Sex may play a role, with some studies suggesting a male predisposition for hemangiosarcoma. Environmental factors, such as exposure to ionizing radiation or certain chemicals, may increase the risk of tumor development. For metastatic cardiac tumors, the presence of a primary malignant neoplasm is the main predisposing factor. Additionally, chronic immunosuppression, as seen in FeLV-positive cats, increases the risk of lymphoma. Obesity and poor nutrition may contribute to overall cancer risk but are not specific to cardiac tumors. Prior chemotherapy or radiation therapy for other cancers could theoretically increase the risk of secondary cardiac tumors, though this is rare.

Clinical signs of cardiac neoplasia are often nonspecific and may be absent in early stages. Common presenting signs include lethargy, weakness, exercise intolerance, and anorexia. As the disease progresses, signs of right-sided congestive heart failure may develop, including ascites, peripheral edema, jugular venous distension, and hepatomegaly. Cardiac tamponade can cause acute collapse, syncope, or sudden death. Arrhythmias, such as atrial fibrillation or ventricular tachycardia, may lead to palpitations or syncope. Respiratory signs, such as dyspnea or cough, can occur due to pleural effusion or pulmonary edema. On physical examination, muffled heart sounds, weak femoral pulses, and tachycardia may be noted. In cases of heart base tumors, a cranial mediastinal mass may be palpable. Neurological signs, such as seizures, can occur due to metastatic spread to the brain. The onset of clinical signs can be acute or chronic, depending on the tumor's growth rate and the development of complications.

Differential diagnoses for cardiac neoplasia include: 1) Pericardial effusion of other causes, such as idiopathic pericarditis, infectious pericarditis (e.g., bacterial, fungal), or pericardial cysts. 2) Dilated cardiomyopathy (DCM), which can cause similar signs of right-sided heart failure and arrhythmias. 3) Valvular heart disease, particularly chronic mitral valve disease, which can lead to left-sided heart failure and arrhythmias. 4) Heartworm disease, which can cause right-sided heart failure and pulmonary hypertension. 5) Congenital heart defects, such as patent ductus arteriosus or ventricular septal defects, which may present with murmurs and heart failure. 6) Other thoracic masses, such as thymoma, lymphoma, or pulmonary tumors, which can cause similar respiratory and systemic signs. 7) Systemic hypertension, which can lead to cardiac remodeling and failure. 8) Myocarditis, which can cause arrhythmias and myocardial dysfunction. Definitive diagnosis requires imaging, echocardiography, and often histopathology.

The diagnostic algorithm for cardiac neoplasia begins with a thorough history and physical examination. If cardiac disease is suspected, thoracic radiographs are obtained to assess cardiac size, shape, and the presence of pleural effusion or pulmonary metastases. Echocardiography is the cornerstone of diagnosis, allowing visualization of pericardial effusion, cardiac masses, and assessment of cardiac function. If a mass is identified, Doppler ultrasound can evaluate blood flow and invasiveness. Electrocardiography (ECG) is performed to detect arrhythmias. If pericardial effusion is present, pericardiocentesis is performed for cytology and fluid analysis, although cytology is often inconclusive for tumor type. Advanced imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), may be used to better characterize the mass and assess for metastasis. In some cases, exploratory thoracotomy or thoracoscopy is necessary for biopsy and surgical resection. Histopathology is required for definitive diagnosis and grading. Additional staging tests include abdominal ultrasound to evaluate for primary tumors or metastasis, and complete blood count, serum biochemistry, and urinalysis to assess overall health.

Laboratory findings in cardiac neoplasia are often nonspecific. Complete blood count may reveal anemia due to chronic disease or hemorrhage, leukocytosis due to inflammation or infection, or thrombocytopenia if disseminated intravascular coagulation (DIC) is present. Serum biochemistry may show elevated liver enzymes (ALT, AST) due to hepatic congestion, elevated BUN and creatinine due to decreased renal perfusion, and hyperglobulinemia or hypercalcemia as paraneoplastic syndromes. Cardiac troponin I (cTnI) levels may be elevated, indicating myocardial damage. Coagulation profiles (PT, aPTT, D-dimer) may be abnormal in cases of DIC. Pericardial fluid analysis typically reveals a modified transudate or hemorrhagic effusion, with a high protein content and variable cellularity. Cytology may show reactive mesothelial cells, inflammatory cells, or neoplastic cells, but is often inconclusive. In cases of lymphoma, fluid cytology may reveal lymphoblasts. Bacterial culture of pericardial fluid is indicated if septic pericarditis is suspected.

Thoracic radiographs may show cardiomegaly, a globoid cardiac silhouette (suggestive of pericardial effusion), or a visible mass at the heart base. Pleural effusion may be present. Echocardiography is the most sensitive imaging modality for cardiac tumors. It can identify pericardial effusion, a mass within the heart or pericardium, and assess the size, location, and echogenicity of the mass. Doppler echocardiography can evaluate blood flow and detect turbulent flow due to obstruction. CT and MRI provide superior anatomical detail and are useful for surgical planning, especially for heart base tumors. CT angiography can delineate vascular involvement. In cases of metastatic disease, thoracic CT can identify pulmonary nodules. Abdominal ultrasound is essential to rule out primary tumors, especially in the spleen or liver, which are common sites for hemangiosarcoma. Fluoroscopy may be used during pericardiocentesis or for guiding biopsy.

Cytology of pericardial fluid is often performed but has limited diagnostic yield for tumor type. Hemorrhagic effusions may contain reactive mesothelial cells that can be mistaken for neoplasia. If neoplastic cells are identified, they may be suggestive of lymphoma, carcinoma, or sarcoma. Histopathology is the gold standard for diagnosis. For right atrial hemangiosarcoma, histology reveals malignant endothelial cells forming irregular vascular channels, with areas of necrosis and hemorrhage. Immunohistochemistry (IHC) can be used to confirm the diagnosis, with positive staining for factor VIII-related antigen or CD31. Heart base tumors (chemodectomas) are composed of nests of polygonal cells with granular cytoplasm, and IHC is positive for chromogranin A and synaptophysin. Mesothelioma shows papillary proliferation of mesothelial cells, with positive staining for cytokeratin and vimentin. Lymphoma is characterized by a monomorphic population of lymphoid cells, with positive staining for CD3 (T-cell) or CD79a (B-cell). Surgical margins are assessed to determine completeness of excision.

Treatment of cardiac neoplasia depends on tumor type, location, and stage. For pericardial effusion causing tamponade, emergency pericardiocentesis is performed to stabilize the patient. Definitive surgical options include subtotal pericardectomy, which can be performed via thoracotomy or thoracoscopy, to prevent recurrence of effusion. For right atrial hemangiosarcoma, surgical resection of the mass with a margin of normal atrial wall is possible if the tumor is localized, but complete excision is often difficult due to invasiveness. Heart base tumors may be resected if they are well-circumscribed, but surgery is challenging due to proximity to great vessels. In cases of non-resectable tumors, palliative pericardiectomy can relieve clinical signs. Chemotherapy is often recommended as an adjunct to surgery, especially for hemangiosarcoma, using protocols such as doxorubicin alone or in combination with cyclophosphamide and vincristine. Radiation therapy may be considered for non-resectable tumors, though its efficacy is limited. For lymphoma, systemic chemotherapy is the primary treatment, with CHOP-based protocols. Supportive care includes management of arrhythmias with antiarrhythmic drugs, diuretics for heart failure, and analgesics for pain.

The prognosis for cardiac neoplasia is generally poor, especially for malignant tumors. For right atrial hemangiosarcoma, the median survival time with surgery alone is approximately 4 months, and with surgery plus chemotherapy, it may be extended to 6-8 months. The presence of metastatic disease at diagnosis significantly worsens the prognosis. Heart base tumors (chemodectomas) have a more variable prognosis, with some dogs surviving for years after surgical debulking or even without treatment, as they are slow-growing. Mesothelioma has a poor prognosis, with median survival times of 2-3 months despite treatment. Lymphoma of the heart carries a guarded prognosis, but with chemotherapy, some cats and dogs may achieve remission for several months. Benign tumors, such as myxomas, have a good prognosis if completely excised. Negative prognostic indicators include right-sided heart failure, cardiac tamponade, arrhythmias, and metastatic disease.

Postoperative follow-up for cardiac neoplasia is crucial. Patients should be monitored closely for recurrence of pericardial effusion or tumor growth. Echocardiography is recommended at 1, 3, 6, and 12 months postoperatively, then every 6-12 months thereafter. Thoracic radiographs should be repeated every 3-6 months to screen for pulmonary metastases. If chemotherapy is administered, regular blood work and physical examinations are necessary to monitor for side effects. Activity restriction is advised for 4-6 weeks after surgery to allow healing. Long-term management includes monitoring for arrhythmias with periodic ECGs and managing heart failure if it develops. Owners should be educated on signs of recurrence, such as lethargy, weakness, or abdominal distension, and advised to seek immediate veterinary care if these occur.

Clinical pearls: 1) Always consider cardiac neoplasia in any dog with unexplained pericardial effusion, especially if the effusion is hemorrhagic and non-clotting. 2) Echocardiography is essential for diagnosis; a mass at the right atrial appendage is highly suggestive of hemangiosarcoma. 3) Pericardiocentesis is both diagnostic and therapeutic; remove as much fluid as possible to relieve tamponade. 4) Subtotal pericardectomy via thoracoscopy is a minimally invasive option that reduces morbidity and provides a biopsy sample. 5) For heart base tumors, surgical resection is risky; consider palliative pericardiectomy if the tumor is non-resectable. Pitfalls: 1) Do not rely solely on pericardial fluid cytology for diagnosis; it is often nondiagnostic. 2) Avoid aggressive surgical resection of right atrial masses without adequate imaging, as the tumor may be more extensive than expected. 3) Do not delay surgery in cases of cardiac tamponade; immediate pericardiocentesis is life-saving. 4) Be cautious with anesthesia in patients with cardiac compromise; use a balanced anesthetic protocol with careful monitoring. 5) Do not forget to stage the patient for metastatic disease, as this significantly impacts prognosis and treatment decisions.

Perioperative antimicrobial prophylaxis: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative analgesia: Opioids such as fentanyl (2-5 mcg/kg/h CRI) or hydromorphone (0.05-0.1 mg/kg IV q4-6h) for the first 24-48 hours. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) can be started after cardiovascular stability is confirmed. Local anesthesia: Intercostal nerve blocks with bupivacaine (1-2 mg/kg) at the incision site. For arrhythmias: Lidocaine (2 mg/kg IV bolus, then 50-80 mcg/kg/min CRI) for ventricular tachycardia; amiodarone (10-15 mg/kg PO q12h) for refractory cases. For heart failure: Furosemide (1-2 mg/kg IV or PO q8-12h) and pimobendan (0.25 mg/kg PO q12h). Chemotherapy protocols: For hemangiosarcoma, doxorubicin (30 mg/m² IV every 3 weeks) alone or in combination with cyclophosphamide (50 mg/m² PO every 3 weeks) and vincristine (0.5 mg/m² IV every 3 weeks). For lymphoma, CHOP protocol: cyclophosphamide (250 mg/m² PO), doxorubicin (30 mg/m² IV), vincristine (0.5 mg/m² IV), and prednisone (2 mg/kg PO q24h). Antiemetics: Maropitant (1 mg/kg SC q24h) for chemotherapy-induced nausea. Gastroprotectants: Omeprazole (1 mg/kg PO q12h) if corticosteroids are used.

The veterinary literature on cardiac neoplasia is limited to retrospective studies and case series. A landmark study by Aronsohn (1985) described the clinical features and surgical outcomes of cardiac tumors in dogs, reporting a median survival of 4 months for right atrial hemangiosarcoma after surgery. A more recent study by Weisse et al. (2005) evaluated the use of pericardectomy for pericardial effusion and found that subtotal pericardectomy provided effective palliation. Another study by Ehrhart et al. (2002) reported on the use of doxorubicin-based chemotherapy for hemangiosarcoma, showing improved survival times when combined with surgery. For heart base tumors, a study by Tobias et al. (2005) found that surgical resection was feasible in some cases, but the prognosis was variable. The ACVS consensus statement on pericardial effusion recommends echocardiography as the primary diagnostic tool and pericardectomy as the treatment of choice for recurrent effusion. Overall, the evidence supports a multimodal approach combining surgery and chemotherapy for malignant cardiac tumors, but the prognosis remains guarded.